Patents by Inventor Kotaro Gotanda
Kotaro Gotanda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9040536Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: GrantFiled: July 31, 2014Date of Patent: May 26, 2015Assignee: ASKA PHARMACEUTICAL CO., LTD.Inventors: Makoto Okada, Shuichiro Sato, Kenji Kawade, Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi
-
Publication number: 20140336197Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: ApplicationFiled: July 31, 2014Publication date: November 13, 2014Inventors: Makoto OKADA, Shuichiro SATO, Kenji KAWADE, Kotaro GOTANDA, Atsushi SHINBO, Youichi NAKANO, Hideo KOBAYASHI
-
Patent number: 8829000Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: GrantFiled: September 14, 2012Date of Patent: September 9, 2014Assignee: ASKA Pharmaceutical Co., Ltd.Inventors: Makoto Okada, Shuichiro Sato, Kenji Kawade, Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi
-
Publication number: 20130225572Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: ApplicationFiled: September 14, 2012Publication date: August 29, 2013Inventors: Makoto OKADA, Shuichiro SATO, Kenji KAWADE, Kotaro GOTANDA, Atsushi SHINBO, Youichi NAKANO, Hideo KOBAYASHI
-
Patent number: 8377944Abstract: This invention provides thienopyrimidine derivatives of the formula, wherein R1 stands for hydrogen atom, an alkyl group or the like; R2 stands for a hydrogen atom, an alkyl or amino group or the like, R3 stands for an alkyl, alkenyl or alkylthio group or the like or a group Y—X—; or R2 and R3 may together form tetramethylene group; X standing for a direct bond or linking group such as CH2, CH(OH), S, O, NH; Y standing for a substituted or unsubstituted aromatic carbocyclic, aromatic heterocylic, cycloalkyl or saturated heterocyclic group or the like; Z stands for S or O, and n is 0 or an integer of 1 to 4, or salts thereof, which exhibit an inhibitory effect on PDE9, and are therefore useful for prevention or treatment of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria associated with prostatic hyperplasia, urolithiasis, Alzheimer's disease, chronic obstructive pulmonary disease, myocardial infarction, thrombosis, diabetes and the like.Type: GrantFiled: August 14, 2012Date of Patent: February 19, 2013Assignee: ASKA Pharmaceutical Co., Ltd.Inventors: Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi, Makoto Okada, Akira Asagarasu
-
Publication number: 20130023546Abstract: This invention provides thienopyrimidine derivatives of the formula, wherein R1 stands for hydrogen atom, an alkyl group or the like; R2 stands for a hydrogen atom, an alkyl or amino group or the like, R3 stands for an alkyl, alkenyl or alkylthio group or the like or a group Y—X—; or R2 and R3 may together form tetramethylene group; X standing for a direct bond or linking group such as CH2, CH(OH), S, O, NH; Y standing for a substituted or unsubstituted aromatic carbocycylic, aromatic heterocylic, cycloalkyl or saturated heterocyclic group or the like; Z stands for S or O, and n is 0 or an integer of 1 to 4, or salts thereof, which exhibit an inhibitory effect on PDE9, and are therefore useful for prevention or treatment of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria associated with prostatic hyperplasia, urolithiasis, Alzheimer's disease, chronic obstructive pulmonary disease, myocardial infarction, thrombosis, diabetes and the like.Type: ApplicationFiled: August 14, 2012Publication date: January 24, 2013Inventors: Kotaro GOTANDA, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi, Makoto Okada, Akira Asagarasu
-
Patent number: 8299080Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: GrantFiled: December 12, 2007Date of Patent: October 30, 2012Assignee: Aska Pharmaceutical Co., Ltd.Inventors: Makoto Okada, Shuichiro Sato, Kenji Kawade, Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi
-
Patent number: 8293754Abstract: This invention provides thienopyrimidine derivatives of the formula, wherein R1 stands for hydrogen atom, an alkyl group or the like; R2 stands for a hydrogen atom, an alkyl or amino group or the like, R3 stands for an alkyl, alkenyl or alkylthio group or the like or a group Y—X—; or R2 and R3 may together form tetramethylene group; X standing for a direct bond or linking group such as CH2, CH(OH), S, O, NH; Y standing for a substituted or unsubstituted aromatic carbocycylic, aromatic heterocylic, cycloalkyl or saturated heterocyclic group or the like; Z stands for S or O, and n is 0 or an integer of 1 to 4, or salts thereof, which exhibit an inhibitory effect on PDE9, and are therefore useful for prevention or treatment of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria associated with prostatic hyperplasia, urolithiasis, Alzheimer's disease, chronic obstructive pulmonary disease, myocardial infarction, thrombosis, diabetes and the like.Type: GrantFiled: June 13, 2006Date of Patent: October 23, 2012Assignee: Aska Pharmaceutical Co., Ltd.Inventors: Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi, Makoto Okada, Akira Asagarasu
-
Publication number: 20100113484Abstract: Disclosed is a treating agent of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria in benign prostatic hyperplasia or urolithiasis, which comprises a compound having PDE9-inhibiting activity as the active ingredient.Type: ApplicationFiled: December 12, 2007Publication date: May 6, 2010Applicant: ASKA PHARMACEUTICAL CO., LTD.Inventors: Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi, Makoto Okada, Akira Asagarasu
-
Publication number: 20100048556Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: ApplicationFiled: December 12, 2007Publication date: February 25, 2010Inventors: Makoto Okada, Shuichiro Sato, Kenji Kawade, Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi
-
Publication number: 20090203703Abstract: This invention provides thienopyrimidine derivatives of the formula, wherein R1 stands for hydrogen atom, an alkyl group or the like; R2 stands for a hydrogen atom, an alkyl or amino group or the like, R3 stands for an alkyl, alkenyl or alkylthio group or the like or a group Y—X—; or R2 and R3 may together form tetramethylene group; X standing for a direct bond or linking group such as CH2, CH(OH), S, O, NH; Y standing for a substituted or unsubstituted aromatic carbocycylic, aromatic heterocylic, cycloalkyl or saturated heterocyclic group or the like; Z stands for S or O, and n is 0 or an integer of 1 to 4, or salts thereof, which exhibit an inhibitory effect on PDE9, and are therefore useful for prevention or treatment of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria associated with prostatic hyperplasia, urolithiasis, Alzheimer's disease, chronic obstructive pulmonary disease, myocardial infarction, thrombosis, diabetes and the like.Type: ApplicationFiled: June 13, 2006Publication date: August 13, 2009Inventors: Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi, Makoto Okada, Akira Asagarasu
-
Patent number: 5221674Abstract: A pyridazinone compound represented by the general formula ##STR1## wherein Ar is ##STR2## in which R.sup.1, R.sup.2 and R.sup.3 may be identical or different, and each represents a hydrogen atom, a lower alkyl group, a trifluoromethyl group, a halogen atom, a cyano group or a nitro group, and R.sup.4 represents a hydrogen atom, a lower alkoxy group, or a lower alkyl group substituted by a lower alkoxy group or a carbamoyl group, and C* is an assymmetric carbon atom,or a salt thereof. This compound is useful for the treatment of diseases of the circulatory system.Type: GrantFiled: September 27, 1991Date of Patent: June 22, 1993Assignee: Teikoku Hormone Mfg. Co., Ltd.Inventors: Kikuo Yasuda, Kenyu Shibata, Nobuyoshi Minami, Toshimi Seki, Masafumi Shiraiwa, Tomio Nakao, Katsuhiko Miyasaka, Tsutomu Ishimori, Kotaro Gotanda, Takako Sasaki
-
Patent number: 5130314Abstract: A pyridazinone compound represented by the general formula ##STR1## wherein Ar is ##STR2## in which R.sup.1, R.sup.2 and R.sup.3 may be identical or different, and each represents a hydrogen atom, a lower alkyl group, a trifluoromethyl group, a halogen atom, a cyano group or a nitro group, and R.sup.4 represents a hydrogen atom, a lower alkoxy group, or a lower alkyl group substituted by a lower alkoxy group or a carbamoyl group, and C* is an assymmetric carbon atom,or a salt thereof. This compound is useful for the treatment of diseases of the circulatory system.Type: GrantFiled: September 27, 1991Date of Patent: July 14, 1992Assignee: Teikoku Hormone Mfg. Co., Ltd.Inventors: Kikuo Yasuda, Kenyu Shibata, Nobuyoshi Minami, Toshimi Seki, Masafumi Shiraiwa, Tomio Nakao, Katsuhiko Miyasaka, Tsutomu Ishimori, Kotaro Gotanda, Takako Sasaki
-
Patent number: 5082844Abstract: A pyridazinone compound represented by the general formula ##STR1## wherein Ar is ##STR2## in which R.sup.1, R.sup.2 and R.sup.3 may be identical or different, and each represents a hydrogen atom, a lower alkyl group, a trifluoromethyl group, a halogen atom, a cyano group or a nitro group, and R.sup.4 represents a hydrogen atom, a lower alkoxy group, or a lower alkyl group substituted by a lower alkoxy group or a carbamoyl group, and C* is an asymmetric carbon atom, or a salt thereof. This compound is useful for the treatment of diseases of the circulatory system.Type: GrantFiled: June 18, 1990Date of Patent: January 21, 1992Assignee: Teikoku Hormone Mfg. Co., Ltd.Inventors: Kikuo Yasuda, Kenyu Shibata, Nobuyoshi Minami, Toshimi Seki, Masafumi Shiraiwa, Tomio Nakao, Katsuhiko Miyasaka, Tsutomu Ishimori, Kotaro Gotanda, Takako Sasaki
-
Patent number: 4843072Abstract: A pyridazinone derivative represented by the following general formula ##STR1## wherein R.sub.1 represents a hydrogen atom or a methyl group, either one of R.sub.2, R.sub.3 and R.sub.4 represents a hydrogen atom and the remaining two of them represent a lower alkyl group, a trifluoromethyl group, a halogen atom, a cyano group or a nitro group, and a salt thereof. The compounds are useful as antihypertensive agents.Type: GrantFiled: September 4, 1987Date of Patent: June 27, 1989Assignee: Teikoku Hormone Mfg. Co., Ltd.Inventors: Kikuo Yasuda, Kenyu Shibata, Seijiro Honma, Toshimi Seki, Kohichi Hasumi, Takeshi Masuda, Akihiro Izumi, Tsutomu Ishimori, Kotaro Gotanda, Masako Uno